Novo Nordisk winds down clinical activities in Russia

Russia’s invasion of Ukraine has now also impacted Danish pharmaceutical firm Novo Nordisk, which has chosen not to initiate new trials in addition to halting patient recruitment for existing ones in the country.

Photo: Novo Nordisk / PR

Novo Nordisk’s clinical activities in Russia will taper off due to the invasion of Ukraine, as reported by Danish business daily Børsen.

This means that the pharmaceutical company has decided not to start new clinical trials in the country and that recruitment for ongoing studies will be paused, meaning no new patients will be enrolled.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs